Ulivi P - Search Results

1

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial.

Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Passardi A, et al. Among authors: ulivi p. Sci Rep. 2017 Sep 5;7(1):10426. doi: 10.1038/s41598-017-11048-9. Sci Rep. 2017. PMID: 28874797 Free PMC article. Clinical Trial.

2

In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.

Ricotti L, Tesei A, De Paola F, Ulivi P, Frassineti GL, Milandri C, Amadori D, Zoli W. Ricotti L, et al. Among authors: ulivi p. Clin Cancer Res. 2003 Feb;9(2):900-5. Clin Cancer Res. 2003. PMID: 12576465

3

NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.

Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W. Tesei A, et al. Among authors: ulivi p. Int J Oncol. 2003 Jun;22(6):1297-302. Int J Oncol. 2003. PMID: 12738997

4

Potentiation of antiproliferative drug activity by lonidamine in hepatocellular carcinoma cells.

Ricotti L, Tesei A, De Paola F, Milandri C, Amadori D, Frassineti GL, Ulivi P, Zoli W. Ricotti L, et al. Among authors: ulivi p. J Chemother. 2003 Oct;15(5):480-7. doi: 10.1179/joc.2003.15.5.480. J Chemother. 2003. PMID: 14598941

5

Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.

Zoli W, Ricotti L, Tesei A, Ulivi P, Gasperi Campani A, Fabbri F, Gunelli R, Frassineti GL, Amadori D. Zoli W, et al. Among authors: ulivi p. Clin Cancer Res. 2004 Feb 15;10(4):1500-7. doi: 10.1158/1078-0432.ccr-1107-03. Clin Cancer Res. 2004. PMID: 14977854

6

c-kit and SCF expression in normal and tumor breast tissue.

Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R. Ulivi P, et al. Breast Cancer Res Treat. 2004 Jan;83(1):33-42. doi: 10.1023/B:BREA.0000010694.35023.9e. Breast Cancer Res Treat. 2004. PMID: 14997053

7

p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients.

Ulivi P, Zoli W, Calistri D, Fabbri F, Tesei A, Rosetti M, Mengozzi M, Amadori D. Ulivi P, et al. J Cell Physiol. 2006 Mar;206(3):611-5. doi: 10.1002/jcp.20503. J Cell Physiol. 2006. PMID: 16222700

8

Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines.

Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Bolla M, Zoli W. Rosetti M, et al. Among authors: ulivi p. Apoptosis. 2006 Aug;11(8):1321-30. doi: 10.1007/s10495-006-6986-x. Apoptosis. 2006. PMID: 16699954

9

Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.

Rosetti M, Zoli W, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D, Silvestrini R. Rosetti M, et al. Among authors: ulivi p. J Cell Physiol. 2007 Sep;212(3):710-6. doi: 10.1002/jcp.21067. J Cell Physiol. 2007. PMID: 17458894

10

Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine.

Vannini I, Bonafe M, Tesei A, Rosetti M, Fabbri F, Storci G, Ulivi P, Brigliadori G, Amadori D, Zoli W. Vannini I, et al. Among authors: ulivi p. Cell Oncol. 2007;29(4):279-87. doi: 10.1155/2007/540821. Cell Oncol. 2007. PMID: 17641412 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

169 results

Search Page